Our Investments

Newton Biocapital's mission is to generate substantial financial and societal value by providing innovative, breakthrough, and affordable solutions to patients.


DIM3 (Disease in management at the 3rd dimension) is a digital healthcare company co-founded in 2012, whose mission is to develop an application to monitor and improve enteral and parenteral nutrition. The company addresses a huge medical need in a space where awareness is currently low.

Logo Epic

EPICS THERAPEUTICS is developing first-in-class drugs in oncology based on RNA epigenetics. The company focuses on discovery and development of small molecule inhibitors of RNA-modifying enzymes to treat cancer.

Syngergia Medical

SYNERGIA is developing a next-generation, small-form, MRI-safe, implanted neurostimulation device for drug-resistant epilepsy, with a range of further therapeutic applications.


ChromaCure is seeking to discover and develop first-in-class small molecule therapeutics for unmet needs in oncology. The company will develop inhibitors of a novel target that is a key regulator of tumor initiation and progression.